GMED

NYSE

GLOBUS MEDICAL INC

Latest disclosureSeptember 16, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 3 sales

Price by TradingView

Insider transactions 14

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. Sales: $2.24M by 1 insider.

Sale disclosed

James R. Tobin

Director

Class A Common Stock

Reported value: $2.24M
Reported price: $74.5834 / share

Sale disclosed

Stephen T. Zarrilli

Director

Class A Common Stock

Reported value: $2.18M
Reported price: $87.0386 / share

Sale disclosed

David D. Davidar

Director

Class A Common Stock

Reported value: $2.02M
Reported price: $80.7629 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
Director	Class A Common StockSale	30,000$74.58 / share	$2.24M	Sep 15Filed Sep 16 · 1d later	SEC filing
Director	Class A Common StockSale	25,000$87.04 / share	$2.18M	Aug 18Filed Aug 19 · 1d later	SEC filing
Director	Class A Common StockSale	25,000$80.76 / share	$2.02M	Jun 5Filed Jun 9 · 4d later	SEC filing

Congress transactions 2

All Congress filings

Purchase disclosed

Globus Medical, Inc. Class A Common Stock (GMED) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: August 19, 2026

Purchase disclosed

Globus Medical, Inc. Class A Common Stock (GMED) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 3, 2026

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001237831
Latest public acceptance: Sep 16, 2026, 08:35 PM UTC
Score calculated: Oct 8, 2026, 12:06 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

Director

Class A Common StockSale

30,000$74.58 / share

$2.24M

Sep 15Filed Sep 16 · 1d later

SEC filing

Director

Class A Common StockSale

25,000$87.04 / share

$2.18M

Aug 18Filed Aug 19 · 1d later

SEC filing

Director

Class A Common StockSale

25,000$80.76 / share

$2.02M

Jun 5Filed Jun 9 · 4d later

SEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001237831
Latest public acceptance: Sep 16, 2026, 08:35 PM UTC
Score calculated: Oct 8, 2026, 12:06 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.